Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- Rossing, Peter
- Agarwal, Rajiv
- Anker, Stefan, D
- Filippatos, Gerasimos
- Pitt, Bertram
- Ruilope, Luis, M
- Amod, Aslam
- Marre, Michel
- Joseph, Amer
- Lage, Andrea
- Scott, Charlie
- Bakris, George, L
DOIAbstract
International audienceAimsFinerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO-DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on the treatment effect of finerenone.Materials and MethodsPatients with type 2 diabetes, urine albumin-to-creatinine ratio (UACR) 30-5000 mg/g and estimated glomerular filtration rate 25-<75 ml/min per 1.73 m2 receiving optimized renin-angiotensin system blockade were randomized to finerenone or placebo.ResultsOf the 5674 patients analysed, overall, 394 (6.9%) received GLP-1RAs at baseline. A reduction in UACR with fi...
Add to ORKG